Administration of voriconazole in patients with renal dysfunction

Clinical Infectious Diseases

Volumn 54, Issue 7, 2012, Pages 913-921

  Neofytos, Dionissios ^a   Lombardi, Lindsey R ^b   Shields, Ryan K ^c   Ostrander, Darin ^a   Warren, Lindsay ^a   Nguyen, M Hong ^c   Thompson, Carol B ^d   Marr, Kieren A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; AMPHOTERICIN B; CARBAPENEM; CEPHALOSPORIN; CORTICOSTEROID; CREATININE; FLUCONAZOLE; IMMUNOSUPPRESSIVE AGENT; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN; VORICONAZOLE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; CREATININE URINE LEVEL; DRUG FORMULATION; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTOR VARIABLE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; CREATININE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY DISEASES; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MYCOSES; PYRIMIDINES; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES; TRIAZOLES; YOUNG ADULT;

EID: 84858145638     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir969     Document Type: Article

References (31)

1. Food and Drug Administration. Antiviral Drugs Advisory Committee/briefing document for voriconazole (oral and intravenous formulations). Available at: http://www.fda.gov/ohrms/dockets/ac/01/briefing/3792b2-01-Pfizer.pdf. Accessed 31 July 2011.
2. Food and Drug Administration. Background document for the Antiviral Drug Products Advisory Committee meeting. Available at: http://www.fda.gov/ohrms/ dockets/ac/01/briefing/3792b2-02-FDAvoriconazole. htm. Accessed 31 July 2011.
3. Luke DR, Tomaszewski K, Damle B, Schlamm HT. Review of the basic and clinical pharmacology of sulfobutylether-beta-cyclodextrin (SBECD). J Pharm Sci 2010; 99:3291-301. Accessed 31 July 2011.
4. von Mach MA, Burhenne J, Weilemann LS. Accumulation of the solvent vehicle sulphobutylether beta cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement therapy. BMC Clin Pharmacol 2006; 6:6.
5. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46:201-11. (Pubitemid 351269158)
6. Trifilio S, Pennick G, Pi J, et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer 2007; 109:1532-5. (Pubitemid 46595688)
7. Abel S, Allan R, Gandelman K, Tomaszewski K, Webb DJ, Wood ND. Pharmacokinetics, safety and tolerance of voriconazole in renally impaired subjects: two prospective, multicentre, open-label, parallelgroup volunteer studies. Clin Drug Investig 2008; 28:409-20. (Pubitemid 351821478)
8. Potoski BA, Sima AP. Effect of intravenous voriconazole on serum creatinine in a population of patients with stable renal dysfunction. In: IDSA-ICAAC Annual Meeting, 25-28 October 2008. Washington, DC. Abstract A-018.
9. Robatel C, Rusca M, Padoin C, Marchetti O, Liaudet L, Buclin T. Disposition of voriconazole during continuous veno-venous haemodiafiltration (CVVHDF) in a single patient. J Antimicrob Chemother 2004; 54:269-70. (Pubitemid 39029007)
10. Fuhrmann V, Schenk P, Jaeger W, et al. Pharmacokinetics of voriconazole during continuous venovenous haemodiafiltration. J Antimicrob Chemother 2007; 60:1085-90. (Pubitemid 47617758)
11. Mohr JF, Finkel KW, Rex JH, Rodriguez JR, Leitz GJ, Ostrosky-Zeichner L. Pharmacokinetics of intravenous itraconazole in stable hemodialysis patients. Antimicrob Agents Chemother 2004; 48:3151-3. (Pubitemid 38989191)
12. Hafner V, Czock D, Burhenne J, et al. Pharmacokinetics of sulfobutylether-beta-cyclodextrin and voriconazole in patients with end-stage renal failure during treatment with two hemodialysis systems and hemodiafiltration. Antimicrob Agents Chemother 2010; 54:2596-602.
13. Burkhardt O, Thon S, Burhenne J, Welte T, Kielstein JT. Sulphobutylether-beta-cyclodextrin accumulation in critically ill patients with acute kidney injury treated with intravenous voriconazole under extended daily dialysis. Int J Antimicrob Agents 2010; 36:93-4.
14. Bellomo R, Ronco C, Kellum JA, et al. Acute Dialysis Quality Initiative workgroup. Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2007; 11:411.
15. de Mattos AM, Olyaei AJ, Bennett WM. Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future. Am J Kidney Dis 2000; 35:333.
16. Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 2009; 4:481.
17. Moore R, Smith C, Lipsjy J, Mellits ED, Lietman PS. Risk factors for nephrotoxicity in patients treated with aminoglycosides. Ann Intern Med 1984; 100:352-7. (Pubitemid 14156536)
18. Peralta CA, Shlipak MG, Fan D, et al. Risks for end-stage renal disease, cardiovascular events, and death in Hispanic versus non-Hispanic white adults with chronic kidney disease. J Am Soc Nephrol 2006; 17:2892.
19. United States Renal Data System 2009 Annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2009. Available at: http://www.usrds.org/adr.htm. (Accessed 20 August 2011).
20. Tareen N, Zadshir A, Martins D, Pan D, Nicholas S, Norris K. Chronic kidney disease in African American and Mexican American populations. Kidney Int Suppl 2005; 97:S78-81.
21. Hsu CY, Lin F, Vittinghoff E, Shlipak MG. Racial differences in the progression from chronic renal insufficiency to end-stage renal disease in the United States. J Am Soc Nephrol 2003; 14:2902.
22. Johnson HJ, Han K, Capitano B, et al. Voriconazole pharmacokinetics in liver transplant recipients. Antimicrob Agents Chemother 2010; 54: 852-9.
23. Amigues I, Cohen N, Chung D, et al. Hepatic safety of voriconazole after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2010; 16:46-52.
24. Tan K, Brayshaw N, Tomaszewski K, Troke P, Wood N. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol 2006; 46:235-43. (Pubitemid 43146453)
25. Food and Drug Administration. Briefing document for voriconazole.2001. Available at: http://www. fda.gov/ohrms/DOCKETS/ac/01/briefing/3792b2-01-Pfizer. pdf (Accessed 1 July 2009).
26. Trifilio S, Ortiz R, Pennick G, et al. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2005; 35:509-13. (Pubitemid 40403355)
27. Lombardi L, Miano T, Davis J, et al. A retrospective analysis of the effect of patient-specific factors on voriconazole concentrations in oncology patients. J Oncol Pharm Pract 2011; 97:S78-81.
28. Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 2009; 49:507-14.
29. Pritchard L, Baker C, Leggett J, Sehgev P, Brown A, Bayley KB. Increasing vancomycin serum trough concentrations and incidence of nephrotoxicity. Amer J Medic 2001; 123:1143-9.
30. Hermsen E, Hanson M, Sankaranarayanan J, Stoner JA, Florescu MC, Rupp ME. Clinical outcomes and nephrotoxicity associated with vancomycin trough concentrations during treatment of deep-seated infections. Expert Opin Drug Saf 2010; 9:9-14.
31. Jeffres M, Isakow W, Doherty J, Micek ST, Kollef MH. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clin Ther 2007; 29:1107-15. (Pubitemid 47208584)